Catalent provides contract development and manufacturing services (CDMO) for the pharmaceutical and biotech industries, offering solutions for drug development, delivery, and supply chain management.

Catalent

Fasteroute - Live Train Info

Fasteroute

Domain Not Resolving

DNSSEC

Google Maps

Cloudflare CDN

IPv6

Cloudflare Hosting

Person Schema

Cloudflare

U.S. Server Location

Facebook Sharer

Rolf Classon

James Quella

Ed Robinson

Melvin Booth

Bruce McEvoy

Jack Stahl

J. Carroll

Paul Clark

Paul Rudd

Director CI and Technology

George Buchman

Research Fellow

Steven Fasman

Senior Vice President & General Counsel

Philip Wills

Chief Commercial Officer, Cell & Gene Therapy

Harshit Agarwal

Scientist

Laura Volpati

Senior Project Manager

Robert Pauli Scherer

Founder

Lisa Gerrizzo-Megarr

Senior Manager & Event Marketing

Acquired Manufacturing Companies (Top 10K)

East Coast Acquired Companies With More Than $50M in Revenue

Supply Chain Management Companies With More Than $100M in Revenue

Somerset Companies

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. 

The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. 

The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. 

The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. 

The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

Post-IPO Debt - Catalent Pharma Solutions

Somerset

New Jersey

United States

North America

Catalent Pharma Solutions

Catalent Pharma Solutions on LinkedIn: Catalent President and CEO, Alessandro Maselli, kicked off Pride month…

Catalent Pharma Solutions’ Post

Kimberly Negrin, Ph.D. on LinkedIn: Catalent is proud to announce our strategic partnership with Siren…

Alan Watts on LinkedIn: Great collaboration between Catalent Pharma Solutions and St. John's…

Catalent Pharma Solutions on LinkedIn: ASGCT | Catalent Cell & Gene Therapy

Catalent Pharma Solutions on LinkedIn: Nicholas Hall's 34th CHC European Conference | Catalent

Catalent Pharma Solutions on LinkedIn: Gummy CDMO | Catalent Consumer Health

Pharmaceutical company Catalent, which has a Bloomington plant, to be acquired by Novo Holdings

Brazil

South America

Argentina

South Korea

Asia

Uruguay

HTML5

Google Drive

Fastly

Adobe Flash

Apache Server

Google Fonts

Bootstrap

Amazon EC2

Microsoft Outlook

jQuery

Catalent Pharma Solutions owns Catalent - Analytical Services Laboratory

Catalent Pharma Solutions owns Catalent

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

news impact assignment basic	general
public peers	general	Sep 27, 2024 4:03 PM	0da56f61
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 4:03 PM	5e63c5da
crunchbase trigger	general	Nov 12, 2024 12:52 PM	1b84c4fa
crunchbase profile	general	Nov 12, 2024 8:50 PM	3ca2951f
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 9:22 PM	de2569ae
peers	general	Sep 27, 2024 4:03 PM	da4dd869
news basic	general	Sep 27, 2024 4:03 PM	927e1f8c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CATALENT

Catalent

Last Close

59.66

22/11 21:00

Market Cap

10.39B

Beta: -

Volume Today

4.87M

Avg: -